NASDAQ · CYCN
Healthcare · Biotechnology
$3.89
Down-$0.18 (-4.42%)
Updated Aug 23, 2026, 11:50 PM
SID Score
6.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
CYCN closed at $3.89 after 20 trading sessions, up 11.14% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $4.07 | $4.2883 | $3.78 | $3.89 | 65.75K |
| Aug 20, 2026 | $4.07 | $4.4682 | $4.0101 | $4.07 | 86.13K |
| Aug 19, 2026 | $4.05 | $4.30 | $4.05 | $4.13 | 14.6K |
| Aug 18, 2026 | $3.92 | $4.25 | $3.8704 | $4.12 | 14.64K |
| Aug 17, 2026 | $3.76 | $4.20 | $3.76 | $4.03 | 15.36K |
| Aug 14, 2026 | $3.85 | $3.9699 | $3.73 | $3.79 | 24.21K |
| Aug 13, 2026 | $3.92 | $4.45 | $3.8072 | $3.91 | 82.97K |
| Aug 12, 2026 | $3.53 | $4.16 | $3.53 | $3.92 | 102.69K |
| Aug 11, 2026 | $3.56 | $3.67 | $3.40 | $3.57 | 10.6K |
| Aug 10, 2026 | $3.51 | $3.73 | $3.51 | $3.58 | 8.35K |
| Aug 7, 2026 | $3.50 | $3.71 | $3.50 | $3.57 | 19.84K |
| Aug 6, 2026 | $3.4101 | $3.70 | $3.4101 | $3.56 | 4.91K |
| Aug 5, 2026 | $3.50 | $3.69 | $3.3986 | $3.55 | 40K |
| Aug 4, 2026 | $3.49 | $3.67 | $3.4347 | $3.51 | 6.37K |
| Aug 3, 2026 | $3.41 | $3.58 | $3.366 | $3.49 | 5.19K |
| Jul 31, 2026 | $3.48 | $3.595 | $3.3606 | $3.44 | 15.71K |
| Jul 30, 2026 | $3.50 | $3.504 | $3.47 | $3.50 | 3.54K |
| Jul 29, 2026 | $3.46 | $3.5999 | $3.4262 | $3.50 | 10.07K |
| Jul 28, 2026 | $3.50 | $3.655 | $3.37 | $3.50 | 18.51K |
| Jul 27, 2026 | $3.41 | $3.55 | $3.41 | $3.50 | 15.8K |
The latest Smart Investors Daily articles mentioning CYCN.
CYCN research
Company profile and research snapshot.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 20, 2021 | Truist Securities | Buy | — |
| Sep 24, 2021 | Cantor Fitzgerald | Overweight | — |
No generated briefing is available yet.
Yahoo · Feb 23, 2026
By David Bautz, PhD NASDAQ:CYCN READ THE FULL CYCN RESEARCH REPORT Business Update Positive Regulatory Feedback Supports Phase 2 Trial Initiation in 2H26 On February 17, 2026, Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) announced that the U.S. Food and Drug Administration (FDA) provided positive written feedback to the company regarding the planned Phase 2 proof-of-concept clinical trial
Yahoo · Feb 17, 2026
–Received Positive Pre-Investigational New Drug (“IND”) Written Feedback from the U.S. Food and Drug Administration (“FDA”)– –Clinical Advisory Board (“CAB”) Includes Key Leaders across Neuropsychiatry, Anesthesiology, and Clinical Development– –Remain On Track to Initiate CYC-126's Phase 2 Proof-of-Concept (“POC”) Study in Treatment Resistant Depression (“TRD”) in the Second Half of 2026– CAMBRIDGE, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) (“Cyclerion
Benzinga · Feb 2, 2026
https://s27.q4cdn.com/906368049/files/News/2026/Zacks_SCR_Research_02022026_CYCN_Bautz.pdf
Yahoo · Feb 2, 2026
By David Bautz, PhD NASDAQ:CYCN READ THE FULL CYCN RESEARCH REPORT Initiating Coverage We are initiating coverage of Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) with a valuation of $8.00. Cyclerion is a clinical-stage biopharmaceutical company that has recently undergone a strategic transformation to focus on the development of novel neuropsychiatric therapies, with an initial emphasis on
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CYCN.
